Biosimilars in immune‐mediated inflammatory diseases: initial lessons from the first approved biosimilar anti‐tumour necrosis factor monoclonal antibody-Reference-Cited by-同舟云学术

Biosimilars in immune‐mediated inflammatory diseases: initial lessons from the first approved biosimilar anti‐tumour necrosis factor monoclonal antibody

Published:2015-09-25 Issue:1 Volume:279 Page:41-59
ISSN:0954-6820
Container-title:Journal of Internal Medicine
language:en
Short-container-title:J Intern Med

Author:

Isaacs J. D.¹,Cutolo M.²,Keystone E. C.³,Park W.⁴,Braun J.⁵

Affiliation:

1. Institute of Cellular Medicine NIHR Newcastle Biomedical Research Centre Newcastle Hospitals NHS Trust and Newcastle University Newcastle upon Tyne UK

2. Research Laboratory and Academic Division of Clinical Rheumatology Department of Internal Medicine University of Genoa Genoa Italy

3. Division of Rheumatology Mount Sinai Hospital University of Toronto Toronto ON Canada

4. Division of Rheumatology Department of Internal Medicine Inha University Hospital Incheon Republic of Korea

5. Rheumazentrum Ruhrgebiet Herne Germany

Funder

Abbott Laboratories

Amgen

AstraZeneca

Bristol-Myers Squibb

Eli Lilly and Company

Novartis

Pfizer

Roche

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/joim.12432

Reference77 articles.

1. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

2. Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis––a multinational cross-sectional study

3. Inequities in access to biologic and synthetic DMARDs across 46 European countries

4. World Health Organization.Expert Committee on Biological Standardization. Geneva 19 to 23 October 2009. Guidelines on evaluation of similar biotherapeutic products (SBPs). Available at:http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf(accessed 1 October 2014).

5. Developing Oncology Biosimilars: An Essential Approach for the Future

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bio‐experienced psoriasis patients treated with anti‐interleukin monoclonal antibodies are less likely to achieve PASI 90, PASI 100, PASI ≤ 1 and ≤3: Results from a cohort of 305 patients;JEADV Clinical Practice;2023-10-09

2. Associations between immune-mediated diseases (IMDs) and the risk of HPV-associated diseases: a UK Biobank cohort analysis;BMJ Open;2023-09

3. How Managed Entry Agreements Influence the Patients’ Affordability to Biological Medicines—Bulgarian Example;Healthcare;2023-08-30

4. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study;Expert Opinion on Investigational Drugs;2023-05-04

5. Biosimilars in Oncology: Latest Trends and Regulatory Status;Pharmaceutics;2022-12-05